182MO Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated overall survival (OS) results of the randomized phase III DESTINY-breast (DB-)02 study

S-B. Kim, F. André, T. Takano, T.N. Fehm,Y.H. Park, J. Lee, G. Santos Borges, M.A. Kaplan, E. Kaczmarek, V. Guarneri, K. Yonemori, T. Pluard, A. Prat, F. Paterson, C. Oakman, S. Nakatani, S. Ashfaque, W. Lu, A. Egorov, I. Krop

ESMO Open（2024）

引用 0|浏览0

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要